A decade ago, when I first returned to the business beat, a company called Dendreon began pushing a non-cure for prostate cancer called Provenge.
The idea was to fit a therapy specifically to a patient’s DNA. This cost a lot of money. While Provenge did extend life, it was only by a few months. For this Dendreon wanted $93,000.
If I had all the money in the world, I’d pay that. But if every prostate cancer patient could force insurers and government agencies to pay that, the system would go broke. You can’t have an unlimited draw from a limited pool of funds. (To the right, at the upper right, is my late mother. I learned recently she taught the first "integrated" second grade class in California history, in 1947. I am very proud of her.)
Fast forward to today. Eli Lilly and Biogen have developed drugs to treat Alzheimer’s Disease.
Recent Comments